|
1
|
Chen W, He Y, Zheng R, Zhang S, Zeng H,
Zou X and He J: Esophageal cancer incidence and mortality in China,
2009. J Thorac Dis. 5:19–26. 2013.PubMed/NCBI
|
|
2
|
Jemal A, Murray T, Ward E, Samuels A,
Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics,
2005. CA Cancer J Clin. 55:10–30. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Olaku O and White JD: Herbal therapy use
by cancer patients: A literature review on case reports. Eur J
Cancer. 47:508–514. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Murakami A, Tanaka T, Lee JY, Surh YJ, Kim
HW, Kawabata K, Nakamura Y, Jiwajinda S and Ohigashi H: Zerumbone,
a sesquiterpene in subtropical ginger, suppresses skin tumor
initiation and promotion stages in ICR mice. Int J Cancer.
110:481–490. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Abdul AB, Abdelwahab SI, Bin Jalinas J,
Al-Zubairi AS and Taha MM: Combination of zerumbone and cisplatin
to treat cervical intraepithelial neoplasia in female BALB/c mice.
Int J Gynecol Cancer. 19:1004–1010. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim M, Miyamoto S, Yasui Y, Oyama T,
Murakami A and Tanaka T: Zerumbone, a tropical ginger
sesquiterpene, inhibits colon and lung carcinogenesis in mice. Int
J Cancer. 124:264–271. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xian M, Ito K, Nakazato T, Shimizu T, Chen
CK, Yamato K, Murakami A, Ohigashi H, Ikeda Y and Kizaki M:
Zerumbone, a bioactive sesquiterpene, induces G2/M cell cycle
arrest and apoptosis in leukemia cells via a Fas- and
mitochondria-mediated pathway. Cancer Sci. 98:118–126. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sakinah SA, Handayani ST and Hawariah LP:
Zerumbone induced apoptosis in liver cancer cells via modulation of
Bax/Bcl-2 ratio. Cancer Cell Int. 7:42007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wiman KG: Pharmacological reactivation of
mutant p53: From protein structure to the cancer patient. Oncogene.
29:4245–4252. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Farnebo M, Bykov VJ and Wiman KG: The p53
tumor suppressor: A master regulator of diverse cellular processes
and therapeutic target in cancer. Biochem Biophys Res Commun.
396:85–89. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oren M and Rotter V: Mutant p53
gain-of-function in cancer. Cold Spring Harb Perspect Biol.
2:a0011072010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Machado-Silva A, Perrier S and Bourdon JC:
p53 family members in cancer diagnosis and treatment. Semin Cancer
Biol. 20:57–62. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chari NS, Pinaire NL, Thorpe L, Medeiros
LJ, Routbort MJ and McDonnell TJ: The p53 tumor suppressor network
in cancer and the therapeutic modulation of cell death. Apoptosis.
14:336–347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vazquez A, Bond EE, Levine AJ and Bond GL:
The genetics of the p53 pathway, apoptosis and cancer therapy. Nat
Rev Drug Discov. 7:979–987. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang NP, Wu YM, Wang B and Ma J:
Systematic review and meta-analysis of the association between P53
codon 72 polymorphism and colorectal cancer. Eur J Surg Oncol.
36:431–438. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tam CW, Liu VW, Leung WY, Yao KM and Shiu
SY: The autocrine human secreted PDZ domain-containing protein 2
(sPDZD2) induces senescence or quiescence of prostate, breast and
liver cancer cells via transcriptional activation of p53. Cancer
Lett. 271:64–80. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oguztüzun S, Aydin M, Demirag F, Yazici U,
Ozhavzali M, Kiliç M and Işcan M: The expression of GST isoenzymes
and p53 in non-small cell lung cancer. Folia Histochem Cytobiol.
48:122–127. 2010.PubMed/NCBI
|
|
18
|
Baker L, Quinlan PR, Patten N, Ashfield A,
Birse-Stewart-Bell LJ, McCowan C, Bourdon JC, Purdie CA, Jordan LB,
Dewar JA, et al: p53 mutation, deprivation and poor prognosis in
primary breast cancer. Br J Cancer. 102:719–726. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cory S, Huang DCS and Adams JM: The Bcl-2
family: Roles in cell survival and oncogenesis. Oncogene.
22:8590–8607. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Packham G and Cleveland JL: c-Myc and
apoptosis. Biochim Biophys Acta. 1242:11–28. 1995.PubMed/NCBI
|
|
21
|
Dworakowska D, Jassem E, Jassem J, Boltze
C, Wiedorn KH, Dworakowski R, Skokowski J, Jaśkiewicz K and
Czestochowska E: Prognostic value of cyclin D1 overexpression in
correlation with pRb and p53 status in non-small cell lung cancer
(NSCLC). J Cancer Res Clin Oncol. 131:479–485. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xi S, Dyer KF, Kimak M, Zhang Q, Gooding
WE, Chaillet JR, Chai RL, Ferrell RE, Zamboni B, Hunt J, et al:
Decreased STAT1 expression by promoter methylation in squamous cell
carcinogenesis. J Natl Cancer Inst. 98:181–189. 2006. View Article : Google Scholar : PubMed/NCBI
|
